advertisement
Esfandiari H 10
Showing records 1 to 10 |
Display all abstracts from Esfandiari H66619 Biometric Changes After Trabeculectomy with Contact and Non-contact BiometryAlvani A
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage GlaucomaPakravan M
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact BiometryPakravan M
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage GlaucomaBeni AN; Ghahari E
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact BiometryEsfandiari H
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage GlaucomaVarshochian R
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact BiometryYaseri M; Yazdani S
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage GlaucomaYazdani S; Esfandiari H
American Journal of Therapeutics 2017; 24: e676-e680
66619 Biometric Changes After Trabeculectomy with Contact and Non-contact BiometryGhahari E
Optometry and Vision Science 2016; 93: 136-140
66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage GlaucomaAhmadieh H
American Journal of Therapeutics 2017; 24: e676-e680
Issue 17-3
Change Issue
advertisement